Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From PuriCore PLC

Troubled Realm Therapeutics Selling Assets, Delisting From London AIM

US-based, UK-listed biotech says it is talking with 'interested parties' including those considering making an offer for the business.

Business Strategies Commercial

Realm Reaches End of The Road And Seeks Buyer

The US company listed in the UK has been devastated by the failure of its investigational eczema drug in Phase II trials in August and has hired an advisor to look for strategic alternatives, including a sale.

Dermatology M & A

New Ways to Attack Atopic Dermatitis: Realm Expects POC Next Quarter

Realm Therapeutics is evaluating a substance derived from insights into innate immunity that has potential as an immunomodulator in various dermatological disorders, including atopic dermatitis and acne, with proof-of-concept (POC) expected in the third quarter.

Clinical Trials Dermatology

Deals Shaping The Medical Industry, July/August 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced May and June 2014.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Services
  • Medical Devices
    • Infection Control-Sterilization